Compare YTRA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YTRA | ACOG |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | India | Canada |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.1M | 129.4M |
| IPO Year | N/A | N/A |
| Metric | YTRA | ACOG |
|---|---|---|
| Price | $1.50 | $5.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 110.4K | 67.8K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $114,229,876.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.62 | $132.35 |
| P/E Ratio | $218.38 | ★ N/A |
| Revenue Growth | ★ 82.82 | N/A |
| 52 Week Low | $0.58 | $3.75 |
| 52 Week High | $2.00 | $11.54 |
| Indicator | YTRA | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | N/A |
| Support Level | $1.38 | N/A |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 18.42 | 0.00 |
Yatra Online Inc is an Indian consumer travel platform provider and online travel agent. The company is organized into the following business segments; Air Ticketing which derives maximum revenue, Hotels and Packages, and Other Services. It mainly provides travel-related services, which include domestic and international air ticketing, hotel bookings, homestays, holiday packages, bus ticketing, rail ticketing, activities and ancillary services. It also involves hosting advertisements on its internet websites, the sale of rail and bus tickets, and facilitating website access to travel insurance companies. Some of its applications include Yatra Mini, Yatra Web Check-In, Yatra Corporate, and Travelguru HomeStay.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.